These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22433170)

  • 1. Post-antibiotic effect of orbifloxacin against Escherichia coli and Pseudomonas aeruginosa isolates from dogs.
    Harada K; Shimizu T; Kataoka Y; Takahashi T
    Acta Vet Scand; 2012 Mar; 54(1):16. PubMed ID: 22433170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant prevention concentration of orbifloxacin: comparison between Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus pseudintermedius of canine origin.
    Shimizu T; Harada K; Kataoka Y
    Acta Vet Scand; 2013 May; 55(1):37. PubMed ID: 23634902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial testing of selected fluoroquinolones against Pseudomonas aeruginosa isolated from canine otitis.
    McKay L; Rose CD; Matousek JL; Schmeitzel LS; Gibson NM; Gaskin JM
    J Am Anim Hosp Assoc; 2007; 43(6):307-12. PubMed ID: 17975212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant prevention concentration and phenotypic and molecular basis of fluoroquinolone resistance in clinical isolates and in vitro-selected mutants of Escherichia coli from dogs.
    Gebru E; Damte D; Choi MJ; Lee SJ; Kim YH; Park SC
    Vet Microbiol; 2012 Jan; 154(3-4):384-94. PubMed ID: 21893387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of pharmacodynamic and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats.
    Boothe DM; Boeckh A; Simpson RB; Dubose K
    J Vet Intern Med; 2006; 20(6):1297-306. PubMed ID: 17186841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
    Pasquali F; Manfreda G
    Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and mechanisms of resistance to fluoroquinolones in Pseudomonas aeruginosa and Escherichia coli isolates recovered from dogs suffering from otitis in Greece.
    Vingopoulou EI; Delis GA; Batzias GC; Kaltsogianni F; Koutinas A; Kristo I; Pournaras S; Saridomichelakis MN; Siarkou VI
    Vet Microbiol; 2018 Jan; 213():102-107. PubMed ID: 29291992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin.
    Odenholt-Tornqvist I; Löwdin E; Cars O
    Antimicrob Agents Chemother; 1992 Sep; 36(9):1852-8. PubMed ID: 1329631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
    Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
    Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus].
    Cetinkaya E; Coban AY; Durupinar B
    Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro killing of Escherichia coli, Staphylococcus pseudintermedius and Pseudomonas aeruginosa by enrofloxacin in combination with its active metabolite ciprofloxacin using clinically relevant drug concentrations in the dog and cat.
    Blondeau JM; Borsos S; Blondeau LD; Blondeau BJ
    Vet Microbiol; 2012 Mar; 155(2-4):284-90. PubMed ID: 21925810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration.
    Heinen E
    J Vet Pharmacol Ther; 2002 Feb; 25(1):1-5. PubMed ID: 11874520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro potency and efficacy favor later generation fluoroquinolones for treatment of canine and feline Escherichia coli uropathogens in the United States.
    Liu X; Boothe DM; Jin Y; Thungrat K
    World J Microbiol Biotechnol; 2013 Feb; 29(2):347-54. PubMed ID: 23136054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae.
    Licata L; Smith CE; Goldschmidt RM; Barrett JF; Frosco M
    Antimicrob Agents Chemother; 1997 May; 41(5):950-5. PubMed ID: 9145850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postantibiotic effect of trovafloxacin against gram-positive and -negative organisms.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1503-5. PubMed ID: 9624503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Pseudomonas aeruginosa isolates from dogs and cats in Japan: current status of antimicrobial resistance and prevailing resistance mechanisms.
    Harada K; Arima S; Niina A; Kataoka Y; Takahashi T
    Microbiol Immunol; 2012 Feb; 56(2):123-7. PubMed ID: 22188523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of canine and feline bacterial pathogens to pradofloxacin and comparison with other fluoroquinolones approved for companion animals.
    Schink AK; Kadlec K; Hauschild T; Brenner Michael G; Dörner JC; Ludwig C; Werckenthin C; Hehnen HR; Stephan B; Schwarz S
    Vet Microbiol; 2013 Feb; 162(1):119-26. PubMed ID: 22939523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant-prevention concentration and mechanism of resistance in clinical isolates and enrofloxacin/marbofloxacin-selected mutants of Escherichia coli of canine origin.
    Gebru E; Choi MJ; Lee SJ; Damte D; Park SC
    J Med Microbiol; 2011 Oct; 60(Pt 10):1512-1522. PubMed ID: 21596912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the in vitro susceptibility of rodent isolates of Pseudomonas aeruginosa and Pasteurella pneumotropica to enrofloxacin.
    Sasaki H; Kawamoto E; Kunita S; Yagami K
    J Vet Diagn Invest; 2007 Sep; 19(5):557-60. PubMed ID: 17823403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of urinary pharmacokinetics and pharmacodynamics of orbifloxacin in healthy dogs with ex vivo modelling.
    Shimizu T; Harada K; Manabe S; Tsukamoto T; Ito N; Hikasa Y
    J Med Microbiol; 2017 May; 66(5):616-621. PubMed ID: 28470147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.